Key facts
- Leaf Biotech’s last known valuation is $198.6M (Jul 2025).
- It has raised $42.0M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include Hefei Industry Investment Group, Hefei Hi-Tech VC, Anyuan Fund, Ciit Asset Management, Amphora Capital China — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Leaf Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Leaf Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leaf Biotech
Developer of the core monomer of bio-based new materials such as furandicarboxylic acid (FDCA) intended to assist in the development of a sustainable environment. The company develops new bio-based polyester material Polyethylene Furanoate (PEF) and its key intermediates, as well as green medicine and health care intermediates, providing sustainable biomass resources.
- Sector
- Materials and Resources
- HQ
- Hefei, China
- Founded
- 2014
- Employees
- 53
- Website
- leafbiotech.com/
- Ownership
- Privately Held (backing)
Leaf Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leaf Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leaf Biotech in its N-PORT filings yet. We sweep new filings monthly.